<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485302</url>
  </required_header>
  <id_info>
    <org_study_id>TDR12399</org_study_id>
    <secondary_id>2011-002910-35</secondary_id>
    <secondary_id>U1111-1120-0550</secondary_id>
    <nct_id>NCT01485302</nct_id>
  </id_info>
  <brief_title>Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients</brief_title>
  <official_title>A Multi-center, Parallel-group, Double-blind, Placebo-controlled Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability and the Pharmacokinetic Properties of SAR228810 Given as IV Infusion or as SC Injection in Patients With Mild to Moderate Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      - To assess the safety and tolerability of escalating single and multiple doses of SAR228810
      in patients with Alzheimer's disease (AD)

      Secondary Objective:

      - To evaluate the pharmacokinetic properties of SAR228810 after escalating single and
      multiple doses of SAR228810 in AD patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      14.5 to 22 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with adverse events</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>1 to 112 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>1 to 112 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2z</measure>
    <time_frame>1 to 112 days after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain magnetic resonance imaging</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematology, biochemistry, coagulation</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs, ECG</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 SC injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR228810</intervention_name>
    <description>Pharmaceutical form:solution
Route of administration: intravenous</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR228810</intervention_name>
    <description>Pharmaceutical form:solution
Route of administration: subcutaneous</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients with mild to moderate Alzheimer's disease, aged between 50 and
             85 years inclusive

          -  Meets criteria for probable Alzheimer's of the National Institute of Neurologic and
             Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders
             Association

          -  Mini-mental state examination (MMSE)

          -  In reasonable and stable health state for Alzheimer's patients of this age and stage
             of disease as assessed by a comprehensive clinical assessment

          -  Magnetic resonance imaging consistent with Alzheimer's disease, not indicating any
             other cause for dementia symptoms than Alzheimer's disease

          -  Rosen Modified Hachinski Ischemic score

          -  If on symptomatic treatment for Alzheimer's disease (acetylcholinesterase inhibitors
             or/and memantine), must be stable in the last 30 days before screening

        Exclusion criteria:

          -  Clinically significant neurological disease other than Alzheimer's disease

          -  Had a major psychiatric disorder

          -  Had a history of stroke, seizures, brain neoplasms, brain surgery, or any
             cerebrovascular disorder (including transient ischemic attack)

          -  History or presence of severe, uncontrolled and/or unstable angiopathy or vasculitis.

          -  History or presence of clinically relevant cardiac disease.

          -  Currently taking anticonvulsants, anti-Parkinsonians, antipsychotics, anticoagulants
             or narcotic drugs, recent immunosuppressive or cancer chemotherapy drugs, or cognitive
             enhancers. Concomitant therapies that are allowed if given at a stable dose for at
             least 30 days before screening are: acetylcholinesterase inhibitors and/or memantine;
             antidepressants of the class of selective serotonin reuptake inhibitors (no
             tricyclics); acetyl salicylic acid (ASA) at a dose ≤ 160 mg/day;

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 100001</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 710001</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752003</name>
      <address>
        <city>Malmö</city>
        <zip>21224</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752002</name>
      <address>
        <city>Mölndal</city>
        <zip>43141</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752001</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild to moderate Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

